Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2756245 | 0.87 | TSHR (0.70) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL7047805 | 0.85 | TSHR (0.68) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL2054452 | 0.84 | TSHR (0.66) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL8519466 | 0.83 | TSHR (0.64) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL10956729 | 0.83 | TSHR (0.64) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL1086346 | 0.81 | TSHR (0.72) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL30686023 | 0.81 | TSHR (0.72) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL15505486 | 0.81 | TSHR (0.67) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL2556953 | 0.81 | TSHR (0.62) | TSHRALDH1A1CES2CES1MAPT | |
| SCHEMBL16959576 | 0.81 | TSHR (0.71) | TSHRALDH1A1CES2CES1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580838-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8410160-B2 | 5-membered heterocycle-based P38 kinase inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-8242117-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8110688-B2 | Method for producing indole derivative having piperidine ring | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| EP-1880995-B1 | METHOD FOR PRODUCING INDOLE DERIVATIVE HAVING PIPERIDINE RING | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2011-03-24 | — | — | US | disclosed |
| US-20100197926-A1 | METHOD FOR PRODUCING INDOLE DERIVATIVE HAVING PIPERIDINE RING | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-1880995-A1 | METHOD FOR PRODUCING INDOLE DERIVATIVE HAVING PIPERIDINE RING | Eisai R&D Management Co., Ltd. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197926-A1 | METHOD FOR PRODUCING INDOLE DERIVATIVE HAVING PIPERIDINE RING | IDO2, IDO1, TPH2 | TSHR 3263/4885ALDH1A1 25/4885CES2 1491/4885 |
| US-20130172352-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | TSHR 3652/4885ALDH1A1 2270/4885CES2 4012/4885 |
| US-20120264801-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | TSHR 3652/4885ALDH1A1 2270/4885CES2 4012/4885 |
| US-20110071152-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | TSHR 3565/4885ALDH1A1 2142/4885CES2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.